Clinical trial EORTC 1209-EnTF
A phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients with either differentiated or medullary thyroid cancer progressing after first line therapy
| Cancers | |
|---|---|
| Organ | Thyroïd |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Non |
| Sponsor | EORTC |
| EudraCT Identifier | 2012-004295-19 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT01788982 |
| Inclusion criteria | At least 1 or 2 prior lines of treatment |
| Last update |